Skip to main content
. 2024 Mar 12;80(6):931–940. doi: 10.1007/s00228-024-03654-0

Table 1.

Baseline characteristics of patients initiating vericiguat between September 2021 and December 2022 in Germany

Total Women Men Age tertile 1: Age tertile 2: Age tertile 3:
(n = 2916) (n = 804) (n = 1934) 20–69 years 70–81 years  ≥ 82 years
(n = 999) (n = 988)  (n = 929)
Sex
   Female 804 (27.6%) n/a n/a 204 (20.4%) 262 (26.5%) 338 (36.4%)
   Male 1934 (66.3%) n/a n/a 725 (72.6%) 668 (67.6%) 541 (58.2%)
   Unknown 178 (6.1%) n/a n/a 70 (7.0%) 58 (5.9%) 50 (5.4%)
Age, years 73.0 (12.7) 75.6 (13.3) 72.3 (12.4) n/a n/a n/a
   18–50 years 160 (5.5%) 45 (5.6%) 96 (5.0%) n/a n/a n/a
   51–60 years 330 (11.3%) 63 (7.8%) 244 (12.6%) n/a n/a n/a
   61–70 years 579 (19.9%) 117 (14.6%) 432 (22.3%) n/a n/a n/a
   71–80 years 806 (27.6%) 214 (26.6%) 548 (28.3%) n/a n/a n/a
   81–90 years 933 (32.0%) 311 (38.7%) 568 (29.4%) n/a n/a n/a
   > 90 years 108 (3.7%) 54 (6.7%) 46 (2.4%) n/a n/a n/a
   Tertile 1: 20–69 years 999 (34.3%) 204 (25.4%) 725 (37.5%) n/a n/a n/a
   Tertile 2: 70–81 years 988 (33.9%) 262 (32.6%) 668 (34.5%) n/a n/a n/a
   Tertile 3: ≥ 82 years 929 (31.9%) 338 (42.0%) 541 (28.0%) n/a n/a n/a
HF co-medicationa
   BB 2207 (75.7%) 614 (76.4%) 1458 (75.4%) 738 (73.9%) 794 (80.4%) 675 (72.7%)
   ACEi 468 (16.0%) 153 (19.0%) 285 (14.7%) 119 (11.9%) 161 (16.3%) 188 (20.2%)
   ARB 357 (12.2%) 136 (16.9%) 194 (10.0%) 86 (8.6%) 125 (12.7%) 146 (15.7%)
   ARNi 1541 (52.8%) 341 (42.4%) 1113 (57.5%) 611 (61.2%) 558 (56.5%) 372 (40.0%)
   Any RASi 2174 (74.6%) 572 (71.1%) 1469 (76.0%) 756 (75.7%) 765 (77.4%) 653 (70.3%)
   MRA 1519 (52.1%) 360 (44.8%) 1064 (55.0%) 604 (60.5%) 542 (54.9%) 373 (40.2%)
   SGLT2i 1479 (50.7%) 328 (40.8%) 1065 (55.1%) 576 (57.7%) 557 (56.4%) 346 (37.2%)
   Diuretic 2244 (77.0%) 635 (79.0%) 1487 (76.9%) 684 (68.5%) 786 (79.6%) 774 (83.3%)
   Digitalis 290 (9.9%) 98 (12.2%) 182 (9.4%) 75 (7.5%) 107 (10.8%) 108 (11.6%)
   Ivabradine 148 (5.1%) 41 (5.1%) 99 (5.1%) 100 (10.0%) 38 (3.8%) 10 (1.1%)
HF drug combinations
   ≤ 1 drug class 616 (21.1%) 205 (25.5%) 370 (19.1%) 205 (20.5%) 160 (16.2%) 251 (27.0%)
   2 drug classes 752 (25.8%) 235 (29.2%) 480 (24.8%) 184 (18.4%) 251 (25.4%) 317 (34.1%)
   3 drug classes 745 (25.5%) 200 (24.9%) 498 (25.7%) 247 (24.7%) 272 (27.5%) 226 (24.3%)
   4 drug classes 803 (27.5%) 164 (20.4%) 586 (30.3%) 363 (36.3%) 305 (30.9%) 135 (14.5%)
Non-HF co-medication
   Oral anticoagulant 1661 (57.0%) 456 (56.7%) 1116 (57.7%) 429 (42.9%) 618 (62.6%) 614 (66.1%)
   Antiplatelet medication 760 (26.1%) 168 (20.9%) 540 (27.9%) 282 (28.2%) 282 (28.5%) 196 (21.1%)
   Lipid-lowering medication 1726 (59.2%) 395 (49.1%) 1226 (63.4%) 563 (56.4%) 661 (66.9%) 502 (54.0%)
   Glucose-lowering medication 814 (27.9%) 207 (25.7%) 566 (29.3%) 252 (25.2%) 334 (33.8%) 228 (24.5%)
   Anti-depressants 365 (12.5%) 137 (17.0%) 206 (10.7%) 121 (12.1%) 122 (12.3%) 122 (13.1%)
   NSAIDs 329 (11.3%) 78 (9.7%) 232 (12.0%) 124 (12.4%) 104 (10.5%) 101 (10.9%)
   Antiobstructive medication 682 (23.4%) 164 (20.4%) 481 (24.9%) 215 (21.5%) 268 (27.1%) 199 (21.4%)
   Gout medication 791 (27.1%) 149 (18.5%) 597 (30.9%) 220 (22.0%) 306 (31.0%) 265 (28.5%)

Data are n (%) or mean (SD)

HF heart failure, BB beta-blockers, MRA mineralocorticoid receptor antagonists, RASi renin–angiotensin system inhibitors, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, ARNi angiotensin receptor–neprilysin inhibitor [ARNi]), SGLT2i sodium-glucose co-transporter-2 inhibitors, NSAIDs non-steroidal anti-inflammatory drug, n/a not available

aUse of co-medication was assessed during the three months prior to vericiguat initiation